The average EPS estimate for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for the three months ending 2016-12-31 is given as $0.21.
You find that 7 days ago, the average EPS estimate on the stock was $0.21, while for the 30 days ago the average EPS estimate stood at $0.21.
If you look back further, you see that the average EPS estimate for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) 60 days ago was given as 0.21, while EPS estimate 90 days ago was quoted at $0.21.
The change in the stock’s EPS estimate over the last 7 days works out to -0.06%.
EPS estimate revisions
Over the last 7 days, EPS estimates for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have been revised up 0 times. In the same period, the EPS estimate has been revised down 2 times.
In the last 30 days, the stock has had its EPS estimate revised up 2 and it has been revised up 2 times over the last 60 days.
Up revisions in the last 90 days are 2 and up revisions in the last 120 days are 1.
But for the last 18 days, the company has seen its EPS revised up 0 times, offset by 3 down revisions in the same period.
The down revisions of EPS in last 30, 60, 90 and 120 days were 3, 3, 3 and 4.
What About EPS Surprises
Analysts predicted EPS of $0.21 for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for the period ended 2. But the company ended up posting actual EPS of $0.18 on 2016-08-02. The EPS estimate cited was worked out based on 6 estimates that analysts had issued on the stock.
Therefore, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) posted EPS surprise of $0.05 per share in dollar terms, which works out to 38.46%. The standard deviation of the actual EPS reported by the company and the average EPS estimate immediately before the earnings were released works out to $0.02.
Quarterly Sales Estimates
For the fiscal year 2016, the mean and median annual sales estimates for the company are given as $58.922 and $58.655. The estimates are based on the projections of 4 analysts.
So far, the highest annual sales estimate for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands at$60.97. That compares with the lowest annual sales estimate of $57.41. Calculating the standard deviation of the extreme annual sales estimates leads you to 1.529%.
Annual sales estimate adjustments
In the last 7 days, 4 analysts have raised their annual sales estimates for the company. But over the same period, 4 analysts have trimmed their annual sales estimates.
With that, you find that the percentage change in mean annual sales estimate in the last 7 days works out to -1.504%.
Over the last one month, though, 4 analysts moved to raise their sales estimates for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). That compares with 4 analysts who cut their sales estimate for the company in the same period. That leads you to -1.162% as the mean sales estimate change over the last one month.
If you look back further, you see that over the last three months, 4 analysts have moved raise their sales estimates Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). That offset by 4 analysts who in the same period lowered their sales estimates for the stock. That works out to percentage change in mean sales estimate of -1.616% over a period of three months.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...